We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Regulus Therapeutics nets $48.3mm through initial public offering
05 Nov 2012
Executive Summary
Less than two months after filing its S-1, Regulus Therapeutics Inc. (single-stranded oligonucleotide therapeutics) has netted $48.3mm in its initial public offering of 12.9mm shares (including the overallotment) for $4. Last month, the company anticipated selling 4.6mm shares at $10-12.
Deal Industry
Pharmaceuticals
Biotechnology
Antisense, Oligonucleotides
Large Molecule
Deal Status
Final
Deal Type
Financing
IPO
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?